Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x100px

Document › Details

Teva Pharmaceutical Industries Ltd.. (2/13/17). "Press Release: Teva Reports Full Year and Fourth Quarter 2016 Financial Results". Jerusalem.

	Organisation	Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
	Group	Teva (Group)
	Organisation 2	Actavis Inc. (new, since Jan 2013)
	Group	Teva (Group)
	Product	pharmaceutical
	Product 2	DRUGS, GENERICS
	Person	Peterburg, Yitzhak (Teva 201702– Interim CEO)

Original document
accessed by [iito] on 2017-02-21

Record changed: 2023-06-05

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Teva (Group)

[1] Rentschler Biopharma SE. (11/16/22). "Press Release: Rentschler Biopharma Appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board". Laupheim....
[2] Formycon AG. (8/29/22). "Press Release: European Commission Approves FYB201/Ranivisio (Ranivisio - Ranibizumab), a Biosimilar to Lucentis". Munich, Amsterdam & Zug....
[3] Oxford Biomedica plc. (7/15/21). "Press Release: Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director". Oxford....
[4] Almirall S.A.. (2/3/21). "Press Release: Almirall Announces Gianfranco Nazzi as New CEO"....
[5] Teva Pharmaceutical Industries Ltd.. (11/7/19). "Press Release: Teva Announces Appointment of New Chief Financial Officer". Jerusalem....
[6] BiomX Ltd.. (10/15/19). "Press Release: BiomX Appoints Merav Bassan as Chief Development Officer". Ness Ziona....
[7] Foundation Medicine, Inc.. (1/7/19). "Press Release: Foundation Medicine Announces Executive Leadership Transition". Cambridge, MA....
[8] Biotechpharma UAB. (10/3/18). "Press Release: Biotechpharma UAB Is Changing Its Management Structure and Appoints Giedrius Žunda as Chief Executive Officer"....
[9] Teva Pharmaceutical Industries Ltd.. (6/15/18). "Press Release: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache". Jerusalem....
[10] Recipharm AB. (2/14/18). "Press Release: Recipharm Appoints President Development Services to Drive End to End Offering"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]